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Abstract
Background: Extensive research efforts have generated genomic, transcriptomic, proteomic, and functional data hoping 
to elucidate psychiatric pathophysiology. Selected reaction monitoring, a recently developed targeted proteomic mass 
spectrometric approach, has made it possible to evaluate previous findings and hypotheses with high sensitivity, 
reproducibility, and quantitative accuracy.
Methods: Here, we have developed a labelled multiplexed selected reaction monitoring assay, comprising 56 proteins 
previously implicated in the aetiology of major psychiatric disorders, including cell type markers or targets and effectors 
of known psychopharmacological interventions. We analyzed postmortem anterior prefrontal cortex (Brodmann area 
10) tissue of patients diagnosed with schizophrenia (n = 22), bipolar disorder (n = 23), and major depressive disorder with 
(n = 11) and without (n = 11) psychotic features compared with healthy controls (n = 22).
Results: Results agreed with several previous studies, with the finding of alterations of Wnt-signalling and glutamate 
receptor abundance predominately in bipolar disorder and abnormalities in energy metabolism across the neuropsychiatric 
disease spectrum. Calcium signalling was predominantly affected in schizophrenia and affective psychosis. Interestingly, 
we were able to show a decrease of all 4 tested oligodendrocyte specific proteins (MOG, MBP, MYPR, CNPase) in bipolar 
disorder and to a lesser extent in schizophrenia and affective psychosis. Finally, we provide new evidence linking ankyrin 
3 specifically to affective psychosis and the 22q11.2 deletion syndrome-associated protein septin 5 to schizophrenia.
Conclusions: Our study highlights the potential of selected reaction monitoring to evaluate the protein abundance levels of 
candidate markers of neuropsychiatric spectrum disorders, providing a high throughput multiplex platform for validation 
of putative disease markers and drug targets.
Keywords: SRMstats, myelination, GSK3b, CamKII, microglia.
Introduction
Psychiatric disorders represent a considerable burden for 
healthcare providers around the world, affecting >20% of the 
global population. Despite extensive research efforts during the 
past decades, the aetiologies of the major psychiatric disorders 
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schizophrenia (SZ), bipolar disorder (BD), and major depressive 
disorder (MDD) are largely unknown. These disorders are het-
erogeneous in nature, with genetic and environmental factors 
contributing to pathogenesis and aetiology (Levinson, 2006; van 
Os and Kapur, 2009; Kim et al., 2011; Craddock and Sklar, 2013; 
Klengel and Binder, 2013). Symptom profiles greatly overlap with 
regards to clinical psychopathology as well as putative patho-
physiology (Smoller et al., 2013). So far, no single gene, mRNA 
transcript, or protein has been found that can account for the 
pathology of any of these disorders. However, the existence of 
a variety of risk genes and risk-associated protein alterations is 
now widely accepted. Genome-wide association studies, iden-
tifying a large number of single nucleotide polymorphisms in 
candidate genes and structural genetic differences such as copy 
number variations, as well as micro-array and proteomic analy-
ses have greatly contributed to this knowledge (Pickard, 2011). 
However, at present, there is a lack of information regarding 
which of the genetic risk polymorphisms are associated with 
changes at the mRNA and protein levels.
Recent technological developments in proteomic methods 
have now made it possible to validate high-throughput findings 
with great accuracy and sensitivity (Wesseling et al., 2014). SRM 
is currently the most advanced targeted mass spectrometry-
based technology. In contrast to shot-gun proteomics strategies, 
in which the goal is to simultaneously investigate abundance 
changes of hundreds to thousands of proteins at the expense of 
sensitivity, SRM mass spectrometry platforms allow monitoring 
of a predetermined selection of proteins/peptides with high sen-
sitivity, reproducibility, and quantitative accuracy (Picotti et al., 
2010; Picotti and Aebersold, 2012). In addition, the SRM approach 
has emerged as an alternative to affinity-based assays such as 
enzyme-linked immune-sorbent assays with the advantage of 
faster and more cost-effective assay development (Whiteaker 
et al., 2011). Protein quantification by SRM in complex samples 
using predefined assay coordinates is reproducible across dif-
ferent laboratories and instrument platforms, facilitating repro-
ducibility of assays in follow-up studies. Developed assays are 
universally applicable to test hypotheses across a variety of 
samples of different origins (eg, brain tissue, blood) and easily 
adjustable to different matrices. Therefore, SRM is ideal to inves-
tigate whether previously reported candidate risk genes for 
psychiatric disorders translate to changes at the protein level, 
providing evidence of functional effects and clinical relevance.
We designed a targeted multiple isotope labelled SRM-assay, 
comprising 56 proteins that have been implicated in the major 
psychiatric disorders and screened a total of 89 postmortem brain 
tissue samples of 22 SZ patients, 23 BD patients, 11 MDD patients, 
11 MDD patients with psychotic features (MDD-P), and 22 healthy 
controls (CTs). The proteins tested have previously been associated 
with psychiatric pathophysiology at the gene, mRNA transcript, or 
protein level. Our main objective was to investigate the potential of 
SRM to systematically elucidate the pathophysiology of neuropsy-
chiatric disorders and to further evaluate putative risk markers as 
novel molecular targets for the next generation of drugs.
Materials and Methods
Clinical Samples
A total of 89 postmortem anterior prefrontal cortex (Broadmann 
Area 10)  brain samples were provided by the Stanley Medical 
Research Institute (Bethesda, MD) (Torrey et  al., 2000) and con-
sisted of 22 SZ patients, 23 BD patients, 11 MDD patients without 
psychotic symptoms, 11 MDD-P patients with psychotic symptoms 
and 22 CTs. Tissue was collected postmortem from patients and 
controls with full informed consent obtained from a first-degree 
relative in compliance with the Declaration of Helsinki, and con-
sent was obtained by questionnaires conducted over the phone 
and signed by 2 witnesses. The sample groups were matched for 
age of death, gender, and brain pH (t test). There were no significant 
differences in the brain side from which samples were obtained, 
secondary axis diagnosis of alcohol abuse/dependency, and drug 
abuse/dependency between patients and CTs (Fisher’s exact test). 
Tissue was sectioned using a Leica Cryostat (Milton Keynes, UK) and 
stored at −80°C until use. All tissue samples used contained equal 
amounts of white and grey matter. A summary of the demographic 
details and statistical values is shown in supplementary Table S1. 
Additional information is provided in supplementary Table S2.
Sample Preparation
Approximately 50 mg of tissue per sample was used. Samples 
were added to fractionation buffer containing 7 M urea, 2 M thio-
urea, 4% CHAPS, 2% ASB14, and 70 mM dithiothreitol at a 5:1 (vol/
wt) ratio (Ernst et al., 2012). After sonication and vortexing for 
30 minutes, protein concentrations of the lysates were deter-
mined using a Bradford assay (Bio-Rad, Hemel Hempstead, UK). 
Protein (approximately 100 μg) was precipitated using acetone. 
After dissolving the precipitate in 50 mM ammonium bicarbo-
nate, protein concentrations were determined in quadruplets. 
Reduction of sulfhydryl groups on proteins was performed 
with 5 mM dithiothreitol at 60°C for 30 minutes and alkylation 
was carried out using 10 mM iodacetamide and incubating in 
the dark at 37°C for 30 minutes. Proteins were digested using 
trypsin at a 1:50 (wt/wt) ratio for 17 hours at 37°C, and reactions 
were stopped by the addition of 8.8 M HCl in a 1:60 (vol/vol) ratio. 
Sample aliquots were stored at −80°C until analysis.
Label-Based Selected Reaction Monitoring Mass 
Spectrometry
Abundance alterations of a panel of 56 candidate proteins impli-
cated in the pathology of the major psychiatric disorders or asso-
ciated with drug treatments were measured using targeted SRM 
mass spectrometry on a Xevo TQ-S mass spectrometer (Waters 
Corporation) coupled online through a New Objective nanoESI 
emitter (7 cm long, 10-mm tip; New Objective) to a nanoAcquity 
UPLC system (Waters Corporation). The system was comprised 
of a C18 trapping column (180 μm x 20 mm, 5-μm particle size) 
and a C18 BEH nano-column (75 μm x 200 mm, 1.7-mm particle 
size). The separation buffers were (A) 0.1% formic acid and (B) 
0.1% formic acid in acetonitrile. For separation of peptides, the 
following 48-minute gradient was applied: 97/3% (A/B) to 60/40% 
in 30 minutes; 60/40% to 15/85% in 2 minutes; 5 minutes at 
15/85%; and returning to the initial condition in 1 minute. The 
flow rate was 0.3 µL/min and the column temperature was 35°C.
SRM assays were developed following a high-throughput 
strategy (Picotti et al., 2010) (Figure 1a). We initially started with 
more than 200 selected proteins. Up to 12 unique peptides rang-
ing from 6 to 20 amino acids in length containing tryptic ends 
and no missed cleavages were chosen for each of the selected 
proteins. All peptides containing amino acids prone to undergo 
modifications (eg, Met, Trp, Asn, and Gln), potential ragged ends, 
lysine/arginine followed by proline, or bearing NXT/NXS glyco-
sylation motifs were avoided and selected only when no other 
options were available (Lange et al., 2008). Peptides were checked 
by Protein BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
searches to ensure uniqueness. For method refinement, up to 
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12 transitions per peptide were tested in SRM mode. Transitions 
were calculated using Skyline version 1.2.0.3425 (MacLean et al., 
2010) and corresponded to singly charged y-ions from dou-
bly or triply charged precursors in the range of 350 to 1250 Da. 
Transitions were selected based on software internal predic-
tions, discovery proteomics data, and spectral data available 
through the Human NIST spectral libraries (Farrah et al., 2011). 
Method refinement was performed on quality control samples. 
For the final SRM assay, the 2 to 3 peptides with the maximal 
intensities and highest spectral library similarity (dotp) were 
selected. We also analyzed heavy-label spiked quality control 
samples (Figure  1b) in scheduled SRM mode to confirm iden-
tity via coelution, extracted the optimal fragment ions for SRM 
analysis, obtained accurate peptide retention times, and opti-
mized collision energy and cone voltage for the quantification 
run applying skyline software (MacCoss Lab Software; Seattle, 
WA) (MacLean et al., 2010). Heavy labelled forms of the selected 
peptides (spiketides L) were chemically synthesized via SPOT 
synthesis (JPT Peptide Technologies GmBH, Berlin, Germany). 
The final transitions, collision energy, and retention time win-
dows used for each peptide can be found in the supplementary 
information (supplementary Table S3).
Quantitative SRM measurements comparing patients and 
controls were performed in scheduled SRM acquisition mode 
using the optimized parameters defined during the assay refine-
ment. For each target peptide, a heavy isotope labelled internal 
standard (JPT Peptide Technologies GmbH) was spiked in the 
peptide mixture for accurate quantification and identification. 
All SRM functions had a 2-minute window of the predicted 
retention time and scan times were 20 milliseconds. For each 
peptide, at least 3 transitions were monitored for the heavy 
and light version. Samples were run randomized and blocked 
(Oberg and Vitek, 2009) in triplicates, and blanks and quality 
control peptide injections (yeast alcohol dehydrogenase; sup-
plementary Table S3) were performed alternating after every 
biological replicate. Resulting SRM data were analyzed using 
Skyline and explanatory data analysis (quality assessment), and 
model-based statistical analysis was conducted using SRMstats 
(Chang et al., 2011). The data preprocessing consisted of a log2 
transformation of the data to stabilise the variance. A constant 
normalization was performed based on reference transitions for 
all proteins to equalize the median peak intensities of reference 
transitions from all proteins across all mass spectrometry runs 
and adjusted the bias to both reference and endogenous signals. 
Protein level quantification and testing for differential abun-
dance among patient and control groups were carried out using 
the linear mixed-effects model implemented in SRMstats. The 
linear mixed model function supported by SRMstats employs 
a “restricted” or “expanded” scope of conclusions (Chang et al., 
2011; Surinova et al., 2013). In the restricted scope model, the 
individual samples being modelled are the population of inter-
est, whereas in the expanded scope model, the samples being 
modelled are treated as a random sample from the population 
of interest. Consequently, the expanded scope model allowed 
us to draw conclusions about the population from which the 
samples were drawn, and the restricted scope allowed conclu-
sions within the data itself. Initially, we assumed the restricted 
scope, taking into account the measurement error of transitions 
across runs (technical variation), to quantify protein abundance 
changes in our sample cohorts. Subsequently, we continued 
with the expanded scope, accounting for technical variation and 
considering the individual biological replicates (biological varia-
tion) of our sample cohorts as random selection of their respec-
tive populations of origin to test which protein changes could 
Figure 1. a, Schematic overview of the study design. b, left, Chromatographic SRM profile of the sample’s endogenic tryptic peptide AIFTGYYGK and of the spiked heavy 
labelled reference peptide. Right, Chromatographic SRM profile of the transitions of the light peptide.
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be considered as representative of their underlying populations. 
The P-values were adjusted to control the false discovery rate at 
a cut-off of 0.05 according to Benjamini and Hochberg (Chang 
et al., 2011).
Results
Applying label-based SRM mass spectrometry, we measured 
differential protein abundance levels of 56 predefined proteins 
(Table 1) in postmortem brain samples from 22 SZ, 23 BD, 11 MDD, 
and 11 MDD-P patients compared with 22 CTs. Additionally, 
MDD-P was compared directly with MDD to identify proteins 
associated with affective psychosis in MDD. We detected com-
mon and unique alterations in individual protein levels across 
the disorders using a statistical modelling framework for pro-
tein significance analysis based on the SRM spectral data. The 
model required the scope of conclusion validity to be specified 
as either “restricted” or “expanded” corresponding to drawing 
conclusions about the data itself or about the population from 
which the individual samples were drawn.
Statistical analysis using the restricted model resulted in the 
identification of 12 differentially expressed proteins in the SZ/
CT, 27 in BD/CT, 11 in MDD/CT, 6 in MDD-P/CT, and 15 in the 
MDD-P/MDD group comparisons (Table 2).
Most alterations in protein abundance levels were found in 
the BD/CT comparison in which the majority of proteins were 
increased, with the exception of oligodendrocyte-specific pro-
teins (CN37, MBP, MOG, MYPR) and neurofilament light poly-
peptide, which were decreased. A less pronounced decrease in 
oligodendrocyte-specific proteins was found in the SZ/CT and 
MDD-P/CT comparisons. In MDD/CT, lower levels of the astro-
cyte marker glial fibrillary acidic protein and the microglia 
marker coronin 1a were identified. In the BD/CT comparison, 
the Wnt signalling pathway appeared to be upregulated. The 
MDD/CT comparison showed increases in calmodulin-depend-
ent protein kinase 2 subunits β and γ as well as ERK signalling. 
All proteins found to be significantly different in MDD-P/MDD 
were decreased similar to the finding in the SZ/CT comparison, 
although this involved different proteins. In the MDD-P/MDD 
comparison, all 3 calmodulin-dependent protein kinase 2 sub-
units (CAMK2α, CAMK2β, CAMK2y) were decreased. To test for 
potential medication effects, we correlated the SRM intensity 
estimates and fluphenazine milligram equivalents and found 
no significant effect on any measured protein (Spearman corre-
lation P > .1). However, effects of other psychotropic medication 
such as antidepressants and mood-stabilizing agents cannot be 
ruled out. To exclude further confounding effects, we correlated 
the SRM intensity estimates and additional demographic char-
acteristics (brain pH, postmortem interval, age of death, age of 
disease onset, disease duration). We were unable to find any cor-
relation (Spearman correlation P > .1). For further information, 
see supplementary Table S6.
Since these proteomic findings resulted from the analysis 
of our sample cohort, we subsequently applied an expanded 
model to determine the likelihood of finding similar results in 
a wider population. These results supported the decrease in oli-
godendrocytic proteins (MBP, MOG, MYP, CN37) in BD/CT and the 
decrease of Septin 5 (SEPT5) in SZ/CT and Ankyrin 3 (ANK3) in 
MDD-P/MDD (Figure 2).
Discussion
This study represents the first and largest label-based quantita-
tive targeted proteomics investigation in human brain tissue to 
date, evaluating expression changes of high-risk genes and risk-
associated proteins in 4 different psychiatric disorders.
Applying linear mixed effect models, we were able to detect a 
range of significantly altered proteins that have been implicated 
at the genetic, transcriptomic, and proteomic levels in psychi-
atric research. We provide evidence for microglial dysfunction 
in MDD (Frick et  al., 2013; Kreisel et  al., 2013) compared with 
controls as shown by a decrease in coronin 1A levels. The astro-
cyte marker glial fibrillary acidic protein was decreased in SZ 
and MDD, indicating a potential disturbance of neuronal main-
tenance and glutamate clearance, and all CamK2 isoforms were 
changed in the MDD-P/MDD comparison. In addition, we identi-
fied a decrease of proteins associated with energy metabolism 
in SZ and an increase in BD and MDD, in line with previous find-
ings (Prabakaran et al., 2004; Marazziti et al., 2012). It is also of 
note that we were able to validate the widely reported expres-
sion changes of malate dehydrogenase in psychiatric disorders.
One of the most striking results in this study was the sys-
tematic decrease of all investigated oligodendrocyte-specific 
proteins in SZ, BD, and MDD-P. Myelin-related abnormalities 
have previously been observed in postmortem brain and imag-
ing studies of SZ and BD (Davis et al., 2003; Dwork et al., 2007; 
Brambilla et  al., 2009; Mcintosh et  al., 2009; Andreasen et  al., 
2011; Bartzokis et al., 2011). In accordance with previous findings 
of mRNA changes (Tkachev et al., 2003), this is the first study 
to show a more prominent decrease in oligodendrocyte-specific 
proteins in BD compared with SZ. Myelination in the prefrontal 
cortex occurs predominantly in adolescence and early adult-
hood (Benes, 1989), consistent with the typical age of onset of SZ 
and BD. Interestingly, myelination deficits in SZ, BD, and MDD-P 
corresponded with changes in the expression of the GSK3β 
and Wnt signalling regulatory protein catenin β in SZ and BD. 
GSK3β is a negative regulator of oligodendrocyte differentiation 
and myelination and has been implicated in BD and SZ. GSK3β 
inhibitors such as lithium are widely prescribed as mood stabi-
lizers in the treatment of BD and are known to increase oligo-
dendrocyte differentiation and promote myelination (Azim and 
Butt, 2011). Furthermore, the NMDA receptor subunit NR1, which 
we found to be upregulated in BD, is a functional regulator of 
oligodendrocyte precursor cell differentiation and remyelina-
tion (Li et al., 2013). Consequently, the development and re-pro-
filing of drugs that promote remyelination may represent novel 
pharmacological targets for psychiatric disorders, especially BD. 
The compound XAV939 has been shown to enhance oligoden-
drocyte differentiation and remyelination by stabilizing Axin2, 
an intracellular target of Wnt transcriptional activation (Fancy 
et  al., 2011). In addition, synthetic and natural cannabinoids 
have been shown to protect oligodendrocytes and oligodendro-
cyte progenitor cells and to enhance myelination by promoting 
oligodendrocyte maturation in vivo and vitro (Molina-Holgado 
et al., 2002; Gomez et al., 2010; Solbrig et al., 2010; Mecha et al., 
2012). They are currently being tested for efficacy in multiple 
sclerosis clinical trials (Zajicek and Apostu, 2011; Velayudhan 
et al., 2013) and could be evaluated for the treatment of SZ and 
BD (Deiana, 2012).
We also found that ANK3 protein levels were reduced in 
affective psychosis, supporting the finding on a wider popula-
tion scale applying the expanded model. The ANK3 protein is 
involved in neuronal scaffolding and the formation and main-
tenance of the axon initial segment of neurons and nodes of 
Ranvier (Bennett and Lambert, 1999). Recently, a meta-analysis 
of the major psychiatric disorders suggested that the ANK3 
locus represents a shared risk gene for a number of psychiatric 
disorders (Smoller et al., 2013). ANK3 polymorphisms have been 
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Table 1. Overview of the Multiplex SRM Assay
Protein Name UP-ID Function Summary CL G T P
Link to
SZ BD MDD
22q11.2 Deletion Syndrome
Catechol O-methyl-
transferase
COMT Catalyzes inactivation, of catecholamine 
neurotransmitters and catechol hormones
22q11.21 √ [1–4] [5, 6] [7]
Proline dehydroge-
nase 1, mito
PROD Converts proline to delta-1-pyrroline-5- 
carboxylate
22q11.21 √ [1, 8, 9]
Ran-binding  
protein 1
RANG Inhibits GTP exchange on Ran. Increases GTP 
hydrolysis induced by RANGAP1
22q11.21 √ [1]
Septin 5 SEPT5 Filament-forming cytoskeletal GTPase, may 
play a role in cytokinesis
22q11.21 √ [1]
TCA transport  
protein, mito
TXTP Involved in citrate-H+/malate exchange 22q11.21 √ [1]
Receptors
Glutamate  
receptor 1
GRIA1 Ionotropic glutamate receptor (AMPA1) 5q31.1 √ [2, 10]
Glutamate  
receptor 2
GRIA2 Ionotropic glutamate receptor (AMPA2) 4q32.1 √ [10–12] [12] [12]
Glutamate  
receptor 3
GRIA3 Ionotropic glutamate receptor (AMPA3) 7q21.1- 
q21.2
√ [10] [12]
NMDA receptor 1 NMDZ1 NMDA receptor subtype, high calcium 
permeability, voltage-dependent sensitivity 
to Mg2+
9q34.3 √ √ √ [10, 13, 14] [15] [16–18]
Scaffolding proteins
Ankyrin 3 ANK3 Neuronal scaffolding protein in nodes of 
Ranvier and axon initial segments
10q21 √ [19, 20] [19, 21, 22] [19]
Disks large homolog 
4 (PSD95)
DLG4 Interacts with the NMDA receptor subunits 
and shaker-type potassium channels
17p13.1 √ √ √ [13, 14, 
23–31]
[13, 23]
Shank3 SHAN3 Post-synaptic density protein, interconnects 
NMDA and metabotropic glutamate receptors
22q13.3 √ [32–34] [35, 36]
Downstream signalling
Calcium signalling
Calmodulin (CaM) CaM Calmodulin mediates the control of a large 
number of enzymes, ion channels by Ca2+
14q32.11 √ [37, 38]
CamK2α KCC2A Major protein kinase in the CNS, functions in 
LTP and neurotransmitter release
5q32 √ √ [39, 40]
CamK2β KCC2B Function autonomously after Ca2+/calmo-
dulin-binding and autophosphorylation, 
involved in dendritic spine and synapse 
formation, neuronal plasticity
7p14.3- 
p14.1
√ [41, 42] [41]
CamK2γ KCC2G 10q22
Calcineurin subunit 
B type 1
CANB1 Regulatory subunit of calcineurin, Ca2+/ 
calmodulin protein phosphatase
2p15 √ [43]
IP3 receptor  
isoform 1
ITPR1 Intracellular channel, mediates calcium 
release from the endoplasmic reticulum
3p26.1 [44]
Neurochondrin NCDN Involved in signal transduction, increases 
cell surface localization of GRM5
1p34.3 [45]
Calmodulin-dep. 
calcineurin A subu-
nit beta isoform
PP2BB Ca2+-dependent, calmodulin-stimulated 
protein phosphatase, may have a role in the 
calmodulin activation of calcineurin.
10q22 √ √ [46, 47]
Protein Kinase
Protein kinase C α 
type
KPCA Ca2+-act. Ser/Thr -protein kinase, involved in 
cell proliferation, apoptosis, differentiation, 
migration
17q22- 
q23.2
√ √ [48, 49] [50]
Protein kinase C β 
type
KPCB Ca2+-act. Ser/Thr-protein kinase involved in 
oxidative stress-induced apoptosis & insulin 
signaling
16p11.2 √ [48, 49] [50, 51]
Protein kinase C γ 
type
KPCG Ca2+-act. Ser/Thr-protein kinase, regulates 
neuronal receptor functions, mediates syn-
aptic function
19q13.4 √ [48, 49]
MARCKS MARCS MARCKS is the most prominent cellular 
substrate for protein kinase C
6q22.2 √ [52–54] [55]
(Continued)
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article-abstract/18/1/pyu015/650770 by Erasm
us U
niversiteit R
otterdam
 user on 13 June 2019
6 | International Journal of Neuropsychopharmacology, 2014
Protein Name UP-ID Function Summary CL G T P
Link to
SZ BD MDD
ERK-signalling
ERK2 MK01 Serine/threonine kinase, essential com-
ponent of the MAPK signal transduction 
pathway
22q11.21 √ [56–58] [59]
ERK1 MK03 Serine/threonine kinase, essential com-
ponent of the MAPK signal transduction 
pathway
16p11.2 √ [56–58]
PED PEA15 Blocks Ras-mediated inhibition of integrin 
activation, modulates the ERK MAP kinase 
cascade
1q21.1 √ [60–62]
mTOR
mTOR MTOR Central regulator of cellular metabolism, 
growth and survival
1p36.2 √ [63]
40S ribosomal  
protein RS3A
RS3A Ribosomal subunit 8q24.3
40S ribosomal  
protein S4, X iso.
RS4X Ribosomal subunit Xq13.1
Wnt signalling
Catenin β-1 CTNB1 Key downstream component of the canoni-
cal Wnt signaling pathway
3p21 √ [64]
Glycogen synthase 
kinase-3 β
GSK3B Active protein kinase, neg. regulator in the 
hormonal control of glucose homeostasis,
3q13.3 √ √ [65–67] [68–72] [73, 74]
Phosphoprotein 
F1-20
AP180 Component of the adapter complexes which 
link clathrin to receptors in coated vesicles
6q14.2 √ [75]
Cell-type specific proteins
Oligodendrocytes
CNPase CN37 Involved in RNA metabolism in the myelinat-
ing cell, third most abundant protein in CNS 
myelin
17q21 √ √ [76–79]
Myelin basic protein MBP Most abundant component of myelin  
membrane, plays role in myelin formation 
and stabilization
18q23 √ √ [2, 80–84] [83] [84]
Myelin proteolipid 
protein
MYPR Major myelin protein from CNS, plays role in 
multi-laminar myelin formation or mainte-
nance
Xq22 √ [85, 86] [87]
Myelin-oligodendro-
cyte glycoprotein
MOG Minor component of the myelin sheath,  
myelin sheath completion/maintenance, 
cell-cell communication
6p22.1 √ [88–90] [88] [87]
Astrocytes
Glial fibrillary acidic 
protein
GFAP GFAP, a class-III intermediate filament, is a 
cell-specific marker for astrocytes
17q21 √ √ [91–94] [95, 96]
Microglia
Coronin-1A COR1A Crucial component of the cytoskeleton of 
highly motile cells
16p11.2 √ √ [94, 
97–100]
Energy metabolism
ATP synthase  
subunit b
ATP5F Mitochondrial membrane ATP synthase 18q21 √ √ √ [101] [102] [103]
Citrate synthase, 
mito
CISY Pace-making enzyme in the first step of the 
tricarboxylic acid cycle (TCA)
12q13.2 √ [104]
Complex I-75 kDa NDUS1 Core subunit of the mitochondrial membrane 
respiratory chain, required for catalysis
2q33-q34 √ √ [105–107] [107, 108] [107]
Malate dehydroge-
nase
MDHC Catalyzes the oxidation of malate to oxalac-
etate, involved in TCA, gluconeogenesis
2p13.3 √ √ √ [11, 78, 105, 
109–112]
Phosphoglycerate 
kinase 1
PGK1 Major ATP-generating enzyme in glycolysis, 
reversed reaction in gluconeogenesis
Xq13.3 √ [113] [114]
Triosephosphate 
isomerase
TPIS Glycolytic enzyme, seems to act as a  
polymerase alpha cofactor protein
12p13 √ [94, 113]
Table 1. Continued
(Continued)
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associated with cognitive and behavioral dysfunction, including 
increased risk taking (Ruberto et al., 2011) and startle response 
(Roussos et al., 2011a), decreased sustained attention (Ruberto 
et  al., 2011; Hatzimanolis et  al., 2012), impaired set-shifting 
(Linke et al., 2012), and increased novelty seeking and anhedo-
nia (Athanasiu et al., 2010; Roussos et al., 2011a). Interestingly, 
common ANK3 risk alleles in BD and SZ have been linked to 
both increased and decreased mRNA expression, dependent 
on the brain region under investigation (Roussos et al., 2011b; 
Rueckert et  al., 2012). The identification of ANK3 in our study 
further supports the pathological relevance of this gene/protein 
in multiple psychiatric disorders and especially in affective psy-
chosis. Neuroimaging studies have associated ANK3 risk alleles 
with decreased white matter integrity in line with our findings 
of decreased oligodendrocyte markers in affective psychosis. 
BD is clinically characterized by a higher frequency of psychotic 
symptoms compared with MDD (Mondimore, 2005), whereas 
other studies have suggested an affective-psychotic continuum 
between MDD, BD, and schizoaffective disorder (Gershon et al., 
1982).
Another interesting finding of our study was a 40% decrease 
in the levels of SEPT5 in SZ patients only, which was supported 
by the population-based model. SEPT5 belongs to a family of 
evolutionarily well-conserved polymerizing GTP-binding pro-
teins that contribute to the lateral compartmentalization of 
membranes, cortical rigidity, and regulation of membrane traf-
ficking (Kinoshita and Noda, 2001). Notably, SEPT5 has been colo-
calized with presynaptic vesicles (Beites et  al., 1999; Kinoshita 
et  al., 2000), plays a role in membrane fusion during neuronal 
exocytosis (Amin et al., 2008), and is critical for dendritic spine 
morphology (Xie et  al., 2007). Decreased levels of SEPT5 in SZ 
prefrontal cortex may be associated with abnormal neurotrans-
mitter secretion, for example glutamatergic hypofunction (Paz 
et al., 2008) and abnormal dendritic spine morphology in the pre-
frontal cortex of SZ patients (Glantz and Lewis, 2000; Broadbelt 
et al., 2002). In terms of pathophysiology, SEPT5 is a strong new 
candidate gene, as it is located on chromosome 22q11.2. In this 
chromosomal region, heterozygous deletions comprising either 
3 or 1.5 Mbp (affecting 90% or 10% of patients, respectively) 
cause the 22q11.2 Deletion Syndrome. The phenotype of this 
syndrome is variable, but characteristic signs and symptoms 
include learning disabilities, dysfunctional social behavior and 
SZ, and autism spectrum disorders. Approximately one-third of 
adults with 22q11.2 Deletion Syndrome develop SZ-like symp-
toms (Karayiorgou et al., 1995; Ivanov et al., 2003; Horowitz et al., 
2005). Interestingly, 3 major SZ susceptibility genes (catechol 
Protein Name UP-ID Function Summary CL G T P
Link to
SZ BD MDD
Oxidative Stress
Catalase CATA Protects cells from the toxic effects of hydro-
gen peroxide
11p13 √ √ [115, 116] [117–120]
Glutathione peroxi-
dase 1
GPX1 Protects the hemoglobin in erythrocytes from 
oxidative breakdown
3p21.3 √ √ [121–123] [124]
Protein DJ-1 PARK7 Protects cells against oxidative stress and 
cell death
1p36.23 √ [104, 125]
Peroxiredoxin-3 PRDX3 Redox regulation of the cell. Protects radical- 
sensitive enzymes from oxidative damage
10q25-q26
Neuronal structure/plasticity
Amyloid beta A4 
protein
A4 cell surface receptor, plays role in neurite 
growth, neuronal adhesion and axonogen-
esis
21q21 √ [126] [127]
BDNF/NT-3 growth 
factors receptor
NTRK2 Receptor tyrosine kinase, involved in the 
nervous system development via regulation 
of neuron survival, proliferation, migra-
tion, differentiation, synapse formation and 
plasticity
9q22.1 √ √ √ [128–130] [128, 131–133] [128, 134–138]
Neural cell adhesion 
molecule 1
NCAM1 Cell adhesion molecule involved in neuron- 
neuron adhesion, neurite fasciculation & 
outgrowth
11q23.1 √ √ [2, 139] [140]
Neuromodulin NEUM Major component of the motile “growth 
cones”, role in axonal and dendritic filopodia 
induction
3q13.31 √ [141, 142] [142]
Neurofilament light 
polypeptide
NFL Maintenance of neuronal caliber 8p21 √ √ [28] [143]
Transcription Factors
Nuclear factor NF- 
kappa-B p105
NFKB1 Pleiotropic transcription factor, endpoint of a 
series of signal transduction events
4q24 √ [144] [145, 146]
Transcriptional acti-
vator protein Purα
PURA Transcription activator, plays a role in the 
initiation of DNA replication and in recom-
bination
5q31 √ [147]
Abbreviations: CL, chromosome location; G, implicated at genetic level; P, implicated at protein level; T, implicated at transcript level; UP-ID, UniProt identification 
code.
Assays were selected based on literature findings. For references, see supplementary Table S4.
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O-methyltransferase, probable palmitoyltransferase, and mito-
chondrial proline dehydrogenase 1) are located in this chromo-
some region. However, it is still unclear which of the deleted 
genes or gene interactions contribute to the risk of developing 
the neuropsychiatric phenotype. The current study provides 
evidence that SEPT5 may represent a novel risk gene for psychi-
atric disorders. As the SEPT5 protein is phosphorylated by cyc-
lin-dependent kinase 5 to modulate exocytotic secretion (Amin 
et al., 2008), drugs targeting this kinase might represent a novel 
treatment approach for SZ. A SEPT5 knockout mouse (Dent et al., 
2002) and a patient case report of SEPT5 deficiency (Bartsch et al., 
2011) demonstrated reduced dense granule secretion in plate-
lets, suggesting that there may be a potential link of this protein 
to the periphery. Three independent studies showed reduced 
platelet-dense granule secretion in first-episode psychosis indi-
viduals and SZ patients (Yao et al., 1994, 1996; Reddy et al., 2007).
In summary, we have employed a hypothesis-driven, label-
based SRM approach and generated the largest quantitative tar-
geted proteomics data set to date in human postmortem brain 
tissue and specifically for neuropsychiatric disorders. We were 
able to confirm changes in protein levels of previously reported 
risk factors for psychiatric disorders and identified novel puta-
tive risk factors for SZ and affective psychosis (SEPT5 and ANK3). 
Testing a wide range of previously described molecular risk 
factors for neuropsychiatric disorders, this is the first study to 
follow up risk genes and validate findings at the protein and 
functional level. We were able to demonstrate that myelination 
abnormalities are prominent in SZ, BD, and affective psychosis, 
as implicated by overlapping changes in several oligodendrocyte 
protein markers. We have also shown that GSK3b and Wnt sig-
nalling is altered in BD and SZ, and CamK2 abnormalities are 
prominently changed in BD and affective psychosis postmortem 
brain, indicating potential novel drug targets.
Our study highlights the potential of SRM to analyze protein 
abundance levels of candidate markers of neuropsychiatric spec-
trum disorders in a highly quantitative manner, thus providing a 
high-throughput multiplex method to validate and quantify poten-
tial disease markers and drug targets. So far, targeted proteomics 
has been employed in only a small number of clinical studies rang-
ing from oncology (Cerciello et  al., 2013) to neurology (Jia et  al., 
2012) and covering a range of biofluids (Shi et al., 2013). Because 
of increased throughput and sensitivity compared with shotgun 
approaches, SRM will enable the evaluation and validation of pro-
tein biomarkers during the hypothesis-generating phase of drug 
discovery. Universally applicable SRM assays for disease-associ-
ated proteins will also accelerate preclinical biomarker discovery 
and validation studies, facilitating the transfer of pathophysiologi-
cal hypotheses towards clinical application and translation.
Supplementary Material
For supplementary material accompanying this paper, visit 
http://www.ijnp.oxfordjournals.org/
Acknowledgments
This research was supported by the Stanley Medical Research 
Institute (SMRI) and the donations of the Stanley brain 
Figure 2. Box plots of the normalized SRM estimates illustrating the proteins detected as significantly changed in the expanded model. Ratios represent disease/CT 
or MDD-P/MDD, respectively.
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article-abstract/18/1/pyu015/650770 by Erasm
us U
niversiteit R
otterdam
 user on 13 June 2019
Wesseling et al. | 11
collection courtesy of Drs. Michael B.  Knable, E.  Fuller Torrey, 
Maree J. Webster, Serge Weis, and Robert H. Yolken. We grate-
fully acknowledge SMRI support. We thank all other members 
of the Bahn laboratory for intellectual and practical input, espe-
cially Drs. Paul Guest and Jason Cooper for their helpful sugges-
tions and discussions throughout the project and proofreading 
of the final manuscript. Michael G. Gottschalk is supported by 
a Gonville & Caius College/Cambridge Home and European 
Scholarship Scheme EU Maintenance Bursary and an EPSRC 
Doctoral Training Grant studentship.
Conflicts of Interest
S.B.  is a consultant for Myriad Genetics Inc and Psynova 
Neurotech Ltd. H.W. and M.G.G. declare no conflicts of interest.
References
Amin ND, Zheng YL, Kesavapany S, Kanungo J, Guszczynski T, Sihag 
RK, Rudrabhatla P, Albers W, Grant P, Pant HC (2008) Cyclin-
dependent kinase 5 phosphorylation of human septin SEPT5 
(hCDCrel-1) modulates exocytosis. J Neurosci 28:3631–3643.
Andreasen NC, Nopoulos P, Magnotta V, Pierson R, Ziebell S, Ho 
BC (2011) Progressive brain change in schizophrenia: a pro-
spective longitudinal study of first-episode schizophrenia. 
Biol Psychiatry 70:672–679.
Athanasiu L et al. (2010) Gene variants associated with schizo-
phrenia in a Norwegian genome-wide study are replicated in 
a large European cohort. J Psychiatr Res 44:748–753.
Azim K, Butt AM (2011) GSK3beta negatively regulates oligoden-
drocyte differentiation and myelination in vivo. Glia 59:540–
553.
Bartsch I, Sandrock K, Lanza F, Nurden P, Hainmann I, Pavlova A, 
Greinacher A, Tacke U, Barth M, Busse A, Oldenburg J, Bom-
mer M, Strahm B, Superti-Furga A, Zieger B (2011) Deletion of 
human GP1BB and SEPT5 is associated with Bernard-Soulier 
syndrome, platelet secretion defect, polymicrogyria, and 
developmental delay. Thromb Haemost 106:475–483.
Bartzokis G, Lu PH, Amar CP, Raven EP, Detore NR, Altshuler LL, 
Mintz J, Ventura J, Casaus LR, Luo JS, Subotnik KL, Nuechter-
lein KH (2011) Long acting injection versus oral risperidone 
in first-episode schizophrenia: differential impact on white 
matter myelination trajectory. Schizophr Res 132:35–41.
Beites CL, Xie H, Bowser R, Trimble WS (1999) The septin 
CDCrel-1 binds syntaxin and inhibits exocytosis. Nat Neurosci 
2:434–439.
Benes FM (1989) Myelination of cortical-hippocampal relays dur-
ing late adolescence. Schizophr Bull 15:585–593.
Bennett V, Lambert S (1999) Physiological roles of axonal 
ankyrins in survival of premyelinated axons and localization 
of voltage-gated sodium channels. J Neurocytol 28:303–318.
Brambilla P, Bellani M, Yeh PH, Soares JC (2009) Myelination in 
bipolar patients and the effects of mood stabilizers on brain 
anatomy. Curr Pharm Des 15:2632–2636.
Broadbelt K, Byne W, Jones LB (2002) Evidence for a decrease in 
basilar dendrites of pyramidal cells in schizophrenic medial 
prefrontal cortex. Schizophr Res 58:75–81.
Cerciello F, Choi M, Nicastri A, Bausch-Fluck D, Ziegler A, Vitek 
O, Felley-Bosco E, Stahel R, Aebersold R, Wollscheid B (2013) 
Identification of a seven glycopeptide signature for malig-
nant pleural mesothelioma in human serum by selected 
reaction monitoring. Clin Proteomics 10:16.
Chang CY, Picotti P, Huttenhain R, Heinzelmann-Schwarz V, 
Jovanovic M, Aebersold R, Vitek O (2011) Protein significance 
analysis in selected reaction monitoring (SRM) measure-
ments. Mol Cell Proteomics 11:M111 014662.
Craddock N, Sklar P (2013) Bipolar Disorder 1 Genetics of bipolar 
disorder. Lancet 381:1654–1662.
Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof 
PR, Buxbaum J, Haroutunian V (2003) White matter changes 
in schizophrenia: evidence for myelin-related dysfunction. 
Arch Gen Psychiatry 60:443–456.
Deiana S (2012) Medical use of cannabis. Cannabidiol: a new 
light for schizophrenia? Drug Test Anal 5:46–51.
Dent J, Kato K, Peng XR, Martinez C, Cattaneo M, Poujol C, Nur-
den P, Nurden A, Trimble WS, Ware J (2002) A prototypic plate-
let septin and its participation in secretion. Proc Natl Acad Sci 
U S A 99:3064–3069.
Dwork AJ, Mancevski B, Rosoklija G (2007) White matter and cog-
nitive function in schizophrenia. Int J Neuropsychopharmacol 
10:513–536.
Ernst A, Ma D, Garcia-Perez I, Tsang TM, Kluge W, Schwarz E, 
Guest PC, Holmes E, Sarnyai Z, Bahn S (2012) Molecular valida-
tion of the acute phencyclidine rat model for schizophrenia: 
identification of translational changes in energy metabolism 
and neurotransmission. J Proteome Res 11:3704–3714.
Fancy SP, Harrington EP, Yuen TJ, Silbereis JC, Zhao C, Baranzini 
SE, Bruce CC, Otero JJ, Huang EJ, Nusse R, Franklin RJ, Rowitch 
DH (2011) Axin2 as regulatory and therapeutic target in new-
born brain injury and remyelination. Nat Neurosci 14:1009–
1016.
Farrah T, Deutsch EW, Omenn GS, Campbell DS, Sun Z, Bletz JA, 
Mallick P, Katz JE, Malmstrom J, Ossola R, Watts JD, Lin BAY, 
Zhang H, Moritz RL, Aebersold R (2011) A high-confidence 
human plasma proteome reference set with estimated con-
centrations in PeptideAtlas. Mol Cell Proteomics 10.
Frick LR, Williams K, Pittenger C (2013) Microglial dysregulation 
in psychiatric disease. Clin Dev Immunol 2013:608654.
Gershon ES, Hamovit J, Guroff JJ, Dibble E, Leckman JF, Sceery 
W, Targum SD, Nurnberger JI, Jr., Goldin LR, Bunney WE Jr. 
(1982) A family study of schizoaffective, bipolar I, bipolar II, 
unipolar, and normal control probands. Arch Gen Psychiatry 
39:1157–1167.
Glantz LA, Lewis DA (2000) Decreased dendritic spine density 
on prefrontal cortical pyramidal neurons in schizophrenia. 
Archives of General Psychiatry 57:65–73.
Gomez O, Arevalo-Martin A, Garcia-Ovejero D, Ortega-Gutierrez 
S, Cisneros JA, Almazan G, Sanchez-Rodriguez MA, Molina-
Holgado F, Molina-Holgado E (2010) The constitutive pro-
duction of the endocannabinoid 2-arachidonoylglycerol 
participates in oligodendrocyte differentiation. Glia 58:1913–
1927.
Hatzimanolis A, Smyrnis N, Avramopoulos D, Stefanis CN, 
Evdokimidis I, Stefanis NC (2012) Bipolar disorder ANK3 risk 
variant effect on sustained attention is replicated in a large 
healthy population. Psychiatr Genet 22:210–213.
Horowitz A, Shifman S, Rivlin N, Pisante A, Darvasi A (2005) A 
survey of the 22q11 microdeletion in a large cohort of schizo-
phrenia patients. Schizophr Res 73:263–267.
Ivanov D, Kirov G, Norton N, Williams HJ, Williams NM, Nikolov I, 
Tzwetkova R, Stambolova SM, Murphy KC, Toncheva D, Thapar 
A, O’Donovan MC, Owen MJ (2003) Chromosome 22q11 dele-
tions, velo-cardio-facial syndrome and early-onset psychosis. 
Molecular genetic study. Br J Psychiatry 183:409–413.
Jia Y, Wu T, Jelinek CA, Bielekova B, Chang L, Newsome S, Gnana-
pavan S, Giovannoni G, Chen D, Calabresi PA, Nath A, Cotter 
RJ (2012) Development of protein biomarkers in cerebrospi-
nal fluid for secondary progressive multiple sclerosis using 
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article-abstract/18/1/pyu015/650770 by Erasm
us U
niversiteit R
otterdam
 user on 13 June 2019
12 | International Journal of Neuropsychopharmacology, 2014
selected reaction monitoring mass spectrometry (SRM-MS). 
Clin Proteomics 9:9.
Karayiorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldberg R, 
Borrow J, Gos A, Nestadt G, Wolyniec PS, Lasseter VK, et al. (1995) 
Schizophrenia susceptibility associated with interstitial dele-
tions of chromosome 22q11. Proc Natl Acad Sci U S A 92:7612–7616.
Kim Y, Zerwas S, Trace SE, Sullivan PF (2011) Schizophrenia 
genetics: where next? Schizophr Bull 37:456–463.
Kinoshita M, Noda M (2001) Roles of septins in the mammalian 
cytokinesis machinery. Cell Struct Funct 26:667–670.
Kinoshita A, Noda M, Kinoshita M (2000) Differential localization 
of septins in the mouse brain. J Comp Neurol 428:223–239.
Klengel T, Binder EB (2013) Gene-Environment Interactions in 
Major Depressive Disorder. Can J Psychiatry 58:76–83.
Kreisel T, Frank MG, Licht T, Reshef R, Ben-Menachem-Zidon O, 
Baratta MV, Maier SF, Yirmiya R (2013) Dynamic microglial 
alterations underlie stress-induced depressive-like behavior 
and suppressed neurogenesis. Mol Psychiatry 19:699–709.
Lange V, Malmstrom JA, Didion J, King NL, Johansson BP, Schafer J, 
Rameseder J, Wong CH, Deutsch EW, Brusniak MY, Buhlmann 
P, Bjorck L, Domon B, Aebersold R (2008) Targeted quantita-
tive analysis of Streptococcus pyogenes virulence factors by 
multiple reaction monitoring. Mol Cell Proteomics 7:1489–1500.
Levinson DF (2006) The genetics of depression: a review. Biol Psy-
chiatry 60:84–92.
Li C, Xiao L, Liu X, Yang W, Shen W, Hu C, Yang G, He C (2013) A 
functional role of NMDA receptor in regulating the differen-
tiation of oligodendrocyte precursor cells and remyelination. 
Glia 61:732–749.
Linke J, Witt SH, King AV, Nieratschker V, Poupon C, Gass A, Hen-
nerici MG, Rietschel M, Wessa M (2012) Genome-wide sup-
ported risk variant for bipolar disorder alters anatomical 
connectivity in the human brain. Neuroimage 59:3288–3296.
MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, 
Frewen B, Kern R, Tabb DL, Liebler DC, MacCoss MJ (2010) Sky-
line: an open source document editor for creating and analyz-
ing targeted proteomics experiments. Bioinformatics 26:966–968.
Marazziti D, Baroni S, Picchetti M, Landi P, Silvestri S, Vatteroni 
E, Catena Dell’Osso M (2012) Psychiatric disorders and mito-
chondrial dysfunctions. Eur Rev Med Pharmacol Sci 16:270–275.
Mcintosh AM, Hall J, Lymer GKS, Sussmann JED, Lawrie SM (2009) 
Genetic risk for white matter abnormalities in bipolar disor-
der. Int Rev Psychiatry 21:387–393.
Mecha M, Torrao AS, Mestre L, Carrillo-Salinas FJ, Mechoulam R, 
Guaza C (2012) Cannabidiol protects oligodendrocyte progen-
itor cells from inflammation-induced apoptosis by attenuat-
ing endoplasmic reticulum stress. Cell Death Dis 3:e331.
Molina-Holgado E, Vela JM, Arevalo-Martin A, Almazan G, 
Molina-Holgado F, Borrell J, Guaza C (2002) Cannabinoids 
promote oligodendrocyte progenitor survival: involvement 
of cannabinoid receptors and phosphatidylinositol-3 kinase/
Akt signaling. J Neurosci 22:9742–9753.
Mondimore FM (2005) Unipolar depression/bipolar depression: 
connections and controversies. Int Rev Psychiatry 17:39–47.
Oberg AL, Vitek O (2009) Statistical design of quantitative mass 
spectrometry-based proteomic experiments. J Proteome Res 
8:2144–2156.
Paz RD, Tardito S, Atzori M, Tseng KY (2008) Glutamatergic dys-
function in schizophrenia: from basic neuroscience to clinical 
psychopharmacology. Eur Neuropsychopharmacol 18:773–786.
Pickard B (2011) Progress in defining the biological causes of 
schizophrenia. Expert Rev Mol Med 13:e25.
Picotti P, Aebersold R (2012) Selected reaction monitoring-based 
proteomics: workflows, potential, pitfalls and future direc-
tions. Nat Methods 9:555–566.
Picotti P, Rinner O, Stallmach R, Dautel F, Farrah T, Domon B, 
Wenschuh H, Aebersold R (2010) High-throughput generation 
of selected reaction-monitoring assays for proteins and pro-
teomes. Nat Methods 7:43–U45.
Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Grif-
fin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, Karp NA, 
Hester S, Tkachev D, Mimmack ML, Yolken RH, Webster MJ, 
Torrey EF, Bahn S (2004) Mitochondrial dysfunction in schizo-
phrenia: evidence for compromised brain metabolism and 
oxidative stress. Mol Psychiatry 9:684–697, 643.
Reddy RD, Keshavan MS, Yao JK (2007) Reduced platelet seroton-
ergic responsivity as assessed by dense granule secretion in 
first-episode psychosis. Clin Biochem 40:1081–1083.
Roussos P, Giakoumaki SG, Georgakopoulos A, Robakis NK, Bit-
sios P (2011a) The CACNA1C and ANK3 risk alleles impact on 
affective personality traits and startle reactivity but not on 
cognition or gating in healthy males. Bipolar Disorders 13:250–
259.
Roussos P, Katsel P, Davis KL, Bitsios P, Giakoumaki SG, Jogia J, 
Rozsnyai K, Collier D, Frangou S, Siever LJ, Haroutunian V 
(2011b) Molecular and genetic evidence for abnormalities in 
the nodes of Ranvier in schizophrenia. Arch Gen Psychiatry 
69:7–15.
Ruberto G, Vassos E, Lewis CM, Tatarelli R, Girardi P, Collier D, 
Frangou S (2011) The cognitive impact of the ANK3 Risk vari-
ant for bipolar disorder: initial evidence of selectivity to sig-
nal detection during sustained attention. Plos One 6.
Rueckert EH, Barker D, Ruderfer D, Bergen SE, O’Dushlaine C, 
Luce CJ, Sheridan SD, Theriault KM, Chambert K, Moran J, 
Purcell SM, Madison JM, Haggarty SJ, Sklar P (2012) Cis-act-
ing regulation of brain-specific ANK3 gene expression by a 
genetic variant associated with bipolar disorder. Mol Psychia-
try 18:922–929.
Shi T, Gao Y, Quek SI, Fillmore TL, Nicora CD, Su D, Zhao R, Kagan 
J, Srivastava S, Rodland KD, Liu T, Smith RD, Chan DW, Camp 
DG II, Liu AY, Qian WJ (2013) A highly sensitive targeted mass 
spectrometric assay for quantification of AGR2 protein in 
human urine and serum. J Proteome Res 13:875–882.
Smoller JW, Craddock N, Kendler K, Lee PH, Neale BM, Nurn-
berger JI, Ripke S, Santangelo S, Sullivan PF, Consortium PG 
(2013) Identification of risk loci with shared effects on five 
major psychiatric disorders: a genome-wide analysis. Lancet 
381:1371–1379.
Solbrig MV, Fan Y, Hermanowicz N, Morgese MG, Giuffrida A 
(2010) A synthetic cannabinoid agonist promotes oligoden-
drogliogenesis during viral encephalitis in rats. Exp Neurol 
226:231–241.
Surinova S, Huttenhain R, Chang CY, Espona L, Vitek O, Aeber-
sold R (2013) Automated selected reaction monitoring data 
analysis workflow for large-scale targeted proteomic studies. 
Nat Protoc 8:1602–1619.
Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, 
Jones PB, Starkey M, Webster MJ, Yolken RH, Bahn S (2003) 
Oligodendrocyte dysfunction in schizophrenia and bipolar 
disorder. Lancet 362:798–805.
Torrey EF, Webster M, Knable M, Johnston N, Yolken RH (2000) 
The Stanley Foundation Brain Collection and Neuropathol-
ogy Consortium. Schizophr Res 44:151–155.
van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635–645.
Velayudhan L, Van Diepen E, Marudkar M, Hands O, Suribhatla 
S, Prettyman R, Murray J, Baillon S, Bhattacharyya S (2014) 
Therapeutic potential of cannabinoids in neurodegenerative 
disorders: a selective review. Curr Pharm Des 20:2218–2230.
Wesseling H, Guest PC, Lago SG, Bahn S (2014) Technologi-
cal advances for deciphering the complexity of psychiatric 
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article-abstract/18/1/pyu015/650770 by Erasm
us U
niversiteit R
otterdam
 user on 13 June 2019
Wesseling et al. | 13
disorders: merging proteomics with cell biology. Int J Neu-
ropsychopharmacol:1–15.
Whiteaker JR et  al. (2011) A targeted proteomics-based pipe-
line for verification of biomarkers in plasma. Nat Biotechnol 
29:625–634.
Xie YL, Vessey JP, Konecna A, Dahm R, Macchi P, Kiebler MA (2007) 
The GTP-binding protein septin 7 is critical for dendrite branch-
ing and dendritic-spine morphology. Curr Biol 17:1746–1751.
Yao JK, Vankammen DP, Gurklis J, Peters JL (1994) Platelet-aggre-
gation and dense granule secretion in schizophrenia. Psychia-
try Res 54:13–24.
Yao JK, vanKammen DP, Moss HB, Sokulski DE (1996) Decreased 
serotonergic responsivity in platelets of drug-free patients 
with schizophrenia. Psychiatry Res 63:123–132.
Zajicek JP, Apostu VI (2011) Role of cannabinoids in multiple scle-
rosis. CNS Drugs 25:187–201. Dow
nloaded from
 https://academ
ic.oup.com
/ijnp/article-abstract/18/1/pyu015/650770 by Erasm
us U
niversiteit R
otterdam
 user on 13 June 2019
